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ABSTRACT
Adenosine receptors (ARs) represent key drug targets in many
human pathologies, including cardiovascular, neurologic, and
inflammatory diseases. To overcome the very rapid metaboliza-
tion of adenosine, metabolically stable AR agonists and antag-
onists were developed. However, few of these molecules have
reached the market due to efficacy and safety issues. Conjuga-
tion of adenosine to squalene to form squalene-adenosine
(SQAd) nanoparticles (NPs) dramatically improved the pharma-
cological efficacy of adenosine, especially for neuroprotection in
stroke and spinal cord injury. However, the mechanism by which
SQAd NPs displayed therapeutic activity remained totally un-
known. In the present study, two hypotheses were discussed: 1)
SQAd bioconjugates, which constitute the NP building blocks,
act directly as AR ligands; or 2) adenosine, once released from
intracellularly processed SQAd NPs, interacts with these
receptors. The first hypothesis was rejected, using radioligand
displacement assays, as no binding to human ARs was detected,
up to 100 mM SQAd, in the presence of plasma. Hence, the
second hypothesis was examined. SQAd NPs uptake by HepG2
cells, which was followed using radioactive and fluorescence
tagging, was found to be independent of equilibrative nucleoside
transporters but rather mediated by low-density lipoprotein
receptors. Interestingly, it was observed that after cell internaliza-
tion, SQAd NPs operated as an intracellular reservoir of adeno-
sine, followed by a sustained release of the nucleoside in the
extracellular medium. This resulted in a final paracrine-like
activation of the AR pathway, evidenced by fluctuations of the
second messenger cAMP. This deeper understanding of the
SQAd NPs mechanism of action provides a strong rational for
extending the pharmaceutical use of this nanoformulation.
Introduction
Adenosine is an endogenous purine acting on four differ-
ent G protein–coupled receptors (GPCRs) identified as A1,
A2A, A2B, and A3. The wide distribution of these adenosine
receptors (ARs) is associated with a great diversity of patho-
physiological effects, including regulation of cardiovascular,
nervous, and immune systems (Fredholm et al., 2011).
Although considerable efforts have been devoted to identifying
new compounds interacting with ARs (Borea et al., 2018), very
few molecules have reached the clinic due to activity and/or
toxicity issues. On the other hand, because of a very short half-
life in the blood circulation (t1/2 5 ∼10 seconds), adenosine
must be administered at high doses, which results in severe
side effects, thus limiting the clinical use of this molecule.
Therefore, innovative pharmaceutical strategies are still
needed to fully exploit adenosine’s tremendous therapeutic
potential.
Currently, the so-called “squalenoylation” approach may
represent a promising technological platform for delivering
hydrophilic compounds with stability issues or off-target
toxicity (Couvreur et al., 2006). This methodology consists
of the conjugation of a fragile and quickly metabolized drug
molecule to the squalene, a natural and biocompatible
lipid. Interestingly, the resulting drug-squalene bioconju-
gates have the unique ability to self-assemble in water as
nanoparticles (NPs). It was found that these squalene-
based NPs favorably modified the in vivo pharmacokinetics
and biodistribution of the conjugated drug molecules
(Reddy et al., 2007). In particular, the delivery of adenosine
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via squalene-adenosine (SQAd) NPs showed an impressive
neuroprotective efficacy in brain ischemia in mice and in
spinal cord injury in rats (Gaudin et al., 2014). This effect
was explained by a prolonged circulation of SQAd NPs in
the bloodstream compared with free adenosine (Gaudin
et al., 2015) and appeared to originate from the interaction
of SQAd NPs with the brain endothelial cells. However, the
nature of the interaction between SQAd NPs and cells still
remains totally unknown.
Thus, the current study aimed at elucidating the mecha-
nism of action of SQAd NPs in vitro. Two hypotheses were
tested: 1) the SQAd NPs or SQAd bioconjugates would act as
direct AR agonists (or antagonists) by binding them via their
adenosine moiety; or 2) they would function as prodrugs by
slowly releasing adenosine intracellularly and into the extra-
cellular space.
The first hypothesis was checked by radioligand displace-
ment assays on membrane fractions of cells overexpressing
human ARs. The second hypothesis was tested on the HepG2
cell line, a well characterized in vitro human hepatocyte
model. Liver cells were chosen for this study, as it has been
previously shown that SQAd NPs accumulate in high
quantities in the liver after their intravenous injection in
mice (Gaudin et al., 2015). The cell capture of SQAd NPs
was followed by radiolabeling and fluorescent labeling, while
adenosine release was determined by high-performance
liquid chromatography (HPLC). Finally, the activation of
the adenosine receptors was also evaluated.
Materials and Methods
Materials. SQAd bioconjugate originated from Holochem (Val-
de-Reuil, France). D-(1)-glucose was obtained from Sigma (St.
Quentin Fallavier, France). Absolute ethanol and methanol came
from VWR Chemicals (Strasbourg, France), while dimethylsulfoxide
(DMSO) was from Carlo Erba Reagents (Val-de-Reuil, France).
MilliQ water (resistivity 18.2 MV·cm) was purified on a system from
Millipore (Molsheim, France). CholEsteryl 4,4-difluoro-5,7-dimethyl-
4-bora-3a,4a-diaza-s-indacene-3-dodecanoate (CholEsteryl BODIPYFLC12)
and wheat germ agglutinin Alexa Fluor 555 conjugate were pur-
chased fromThermo Fisher Scientific (Karlsruhe, Germany). [2,8-3H]-
Adenosine (specific activity 20.3 Ci/mmol) was obtained from
Moravek Biochemicals (Brea, CA), while SQ-[3H]-adenosine (SQ-
[3H]-Ad) (specific activity 2.8 Ci/mmol) was synthetized as pre-
viously reported (Gaudin et al., 2014). Soluene-350 and Hionic
Fluor were provided by PerkinElmer (Courtaboeuf, France). Radio-
ligands 1,3-[3H]-dipropyl-8-cyclopentylxanthine ([3H]DPCPX, spe-
cific activity 120 Ci/mmol) and [2-3H]-4-(2-[7-amino-2-{2-furyl}
{1,2,4}triazolo{2,3-a}{1,3,5,}triazin-5-yl amino]ethyl)phenol ([3H]
ZM241385, specific activity 50 Ci/mmol) were purchased from
ARC Inc. (St. Louis, MO). [3H]8-(4-(4-(4-Chlorophenyl)piperazide-
1-sulfonyl)phenyl)-1-propylxanthine ([3H]PSB603, specific activity
79 Ci/mmol) and [3H]8-ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-
tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([3H]PSB11, specific activ-
ity 56 Ci/mmol) were kindly provided by C. E. Müller (University of
Bonn,Germany). 59-N-ethylcarboxamidoadenosinewas purchased from
Sigma-Aldrich (Steinheim, Germany). N6-cyclopentyladenosine
was purchased from Abcam (Cambridge, UK). Unlabeled 4-(-2-[7-
amino-2-{2-furyl}{1,2,4}triazolo{2,3-a}{1,3,5}triazin-5-yl-amino]ethyl)-
phenol (ZM241385) was a gift from Dr. S. M. Poucher (Astra Zeneca,
Macclesfield, UK). Adenosine deaminase was purchased from Boeh-
ringer Mannheim (Mannheim, Germany). Bicinchoninic acid and
bicinchoninic acid protein assay reagent were obtained from Pierce
Chemical Company (Rockford, IL). Chinese hamster ovary (CHO) cells
stably expressing the human A1, A2B, or A3 ARs were provided by
S. J. Hill (University of Nottingham, UK), Dr. S. Rees (AstraZeneca),
and Dr. K.-N. Klotz (University of Würzburg, Germany), respectively.
HEK293 cells stably expressing the human A2A AR were kindly
provided by Dr. J. Wang (Biogen/IDEC, Cambridge, MA). The
hCMEC/D3 cell line was a gift from Dr. Couraud (Hôpital Cochin,
Paris, France). The HepG2 cell line, Dulbecco’s modified Eagle’s
medium high glucose, Dulbecco’s phosphate-buffered saline (PBS),
lipoprotein deficient serum (LPDS) from fetal calf, trypsin and
penicillin-streptomycin, HEPES, hydrocortisone, basic fibroblast
growth factor, ascorbic acid, adenosine, cathepsin B from human
liver, theophylline, dipyridamole, erythro-9-(2-hydroxy-3-nonyl)-
adenine (EHNA) hydrochloride, paraformaldehyde, isobutyl-
1-methylxanthine, and 4-(3-butoxy-4-methoxybenzyl)imidazolidone
(Ro 20-1724) were obtained from Sigma. Endothelial basal medium
was purchased from Lonza (Basel, Switzerland). Gibco fetal bovine
serum (FBS) was obtained from Life Technologies (Saint-Aubin,
France).
All other chemicals were of analytical grade andwere obtained from
standard commercial sources.
SQAd NPs Preparation. SQAdNPs were prepared as previously
described (Gaudin et al., 2014). In brief, 333 ml of an ethanolic solution
of 6 mg/ml SQAd was added dropwise into 1 ml of a solution of 5 wt. %
dextrose under stirring. Ethanol was then removed by evaporation
using a Rotavapor (Buchi, Rungis, France) to obtain a final concen-
tration of 2 mg/ml SQAd NPs. Radiolabeled NPs were obtained
following the same procedure, with the addition of SQ-[3H]-Ad to the
ethanolic SQAd solution (final radioactivity 10 Ci/mol). Similarly,
fluorescently labeled SQAd NPs were prepared by adding 40 ml of
CholEsteryl BODIPY FL C12 to the 333-ml ethanolic SQAd solution
(the final concentration of fluorescent probe was 1 wt. %). Excitation
and emission spectra were recorded using an LS 50B Luminescence
Spectrometer (PerkinElmer) (Supplemental Fig. 1).
ThemeanNP size and polydispersity index (PdI) were checked from
1-mg/ml suspensions by dynamic light scattering using a Zetasizer
Nano ZS (173° scattering angle, 25°C; Malvern, UK).
Radioligand Displacement Assay. CHO orHEK293 cells stably
expressing the human A1, A2A, A2B or A3 ARs were cultured, and
membranes were prepared as previously described (Heitman et al.,
2009; Yang et al., 2017). Buffer compositions, membrane concentra-
tions, radioligands, and nonspecific binding compounds used for
each receptor type, as well as their concentrations, are listed in
Supplemental Table 1.
For radioligand displacement assays, membrane aliquots at given
concentrations (Supplemental Table 1) were incubated in a total
volume of 100 ml of assay buffer (Supplemental Table 1) at 25°C for
60 minutes (A1) to 120 minutes (other receptors). The DMSO stock
solution of SQAd as single bioconjugate molecules or the SQAd NPs
preparation were diluted in assay buffer or FBS (DMSO final
concentration,1%). Samples with serumwere incubated for 4 hours
at 37°C on an Eppendorf Thermomixer before the experiment.
Displacement experiments were performed in the presence of
specific radioligands at given concentrations (Supplemental Table 1),
while nonspecific binding was determined in the presence of non-
specific binding compounds at given concentrations (Supplemental
Table 1). Incubations were terminated by dilutionwith ice-cold assay
buffer, immediately followed by separation of bound from free
radioligand by rapid filtration through 96-well GF/B filter plates
using a PerkinElmer FilterMate Harvester (PerkinElmer, Gronin-
gen, Netherlands). Filters were subsequently washed three times
with 2 ml of ice-cold washing buffer (Supplemental Table 1). The
filter-bound radioactivity was determined by scintillation spectrom-
etry using a P-E 1450 Microbeta Wallac Trilux scintillation counter
(PerkinElmer). IC50 values were obtained by fitting the curves with a
one-site binding model using GraphPad Prism 7.00 software. Ki
values were deduced using the Cheng-Prusoff equation (Cheng and
Prusoff, 1973).
Cell Culture. HepG2 cells were cultured in Dulbecco’s modi-
fied Eagle’s medium high-glucose medium supplemented with 10%











FBS, penicillin (50 U/ml), and streptomycin (50 mg/ml). If not stated
otherwise, cells were plated on 24-well plates at a density of 200,000
cells per well and left to adhere overnight before any further
procedure.
hCMEC/D3 cells were cultured in endothelial basal medium
supplemented with 5% FBS; penicillin (50 U/ml) and streptomycin
(50 mg/ml); 1.4 mM hydrocortisone; 5 mg/ml ascorbic acid; 1%
chemically defined lipid concentrate; 10 mM HEPES; and 1 ng/ml
basic fibroblast growth factor. Cells were used between passages 4 and
8. Cells were plated on 24-well plates at a density of 100,000 cells per
well and left to adhere overnight before any further procedure.
All cells were maintained at 37°C, 5% CO2, 100% humidity. Cells
were passaged twice a week.
Cell Uptake of Radiolabeled SQAd NPs and Free Adenosine.
HepG2 cells were treatedwith radiolabeled SQAdNPs or radiolabeled
free adenosine at concentrations of 10 mMand 0.1 mCi/ml. At different
time points, cells were washed twice with PBS and detached with
trypsin before being pelleted and resuspended in PBS. Sample
radioactivity was measured using a b-scintillation counter (LS6500;
BeckmanCoulter) after overnight incubationwith 1ml of Soluene-350
at 50°C and addition of 10 ml of Hionic Fluor.
Cell Uptake of Fluorescently Labeled SQAd NPs. For confo-
cal microscopy imaging, HepG2 cells were plated onto sterile glass
coverslips placed in 24-well plates, at a density of 50,000 cells per well,
and left to adhere for 48 hours. Cellswere incubatedwith fluorescently
labeled SQAd NPs (10 mg/ml) for 2 hours at 37°C. After several
washing stepswith PBS,membraneswere stained for 20minuteswith
10 mg/ml of wheat germ agglutinin Alexa Fluor 555. Cells were then
washed again and fixed with 4% paraformaldehyde for 15 minutes.
After final washing, coverslips were mounted on slides using Vecta-
shield mounting medium with 49,6-diamidino-2-phenylindole (Vector
Labs) and sealed with nail polish. Images were acquired using a Leica
TCS SP8 system, with a Leica HC Plan Apochromat 63/1.4NO oil
CS2 objective lens.
For studying the role of adenosine transporters, HepG2 cells were
treated with fluorescently labeled SQAd NPs (10 mg/ml) and
dipyridamole (20 mM). For studying the role of low-density lipopro-
tein receptors (LDLRs) in SQAd NPs cell uptake, 150,000 cells were
plated by well. Cells were washed with PBS, and medium was
replaced with normal medium or medium supplemented with LPDS
instead of FBS. Cells were then incubated for 24 hours to enhance
LDLR expression, as proven by Western blot [protocol from Sobot
et al. (2017a); Supplementary Fig. 2)], and subsequently treated
with fluorescently labeled SQAd NPs (10 mg/ml). In both cases, after
30 minutes or 2 hours, cells were finally washed with PBS, detached
with trypsin, and resuspended in PBS. Cell fluorescence was
evaluated using a BD Accuri C6 flow cytometer (BD Biosciences)
with an excitation wavelength of 488 nm. Emission was recorded
with the FL1 filter (533/30 nm).
SQAd Degradation in Acidic Conditions. A solution of 1 ml of
SQAd (2.5 mg/ml dissolved in DMSO) was incubated at 37°C under
shaking in 100 ml of 0.3 M sodium acetate buffer (pH 4.8) containing
cathepsin B (10 U/ml). Degradation was stopped at different time
points by the addition of 233 ml of methanol. Five microliters of
gemcitabine-squalene (0.2 mg/ml dissolved in DMSO) was added as
internal standard. Samples were centrifuged (14,000 rpm, 10minutes),
and resulting supernatants were evaporated to dryness at 37°C under
airflow. The dried samples were then dissolved in 100 ml of mobile
phase [methanol for SQAd detection; methanol/KH2PO4 (10 mM,
pH 4), 20/80 v/v, for adenosine detection] prior to HPLC analysis.
Adenosine Extracellular Release. HepG2 or hCMEC/D3 cells
were treated with SQAd NPs (100 mM), free adenosine dissolved in
5 wt. % dextrose (100 mM), or 5 wt. % dextrose. After 5 minutes to
4 hours, extracellular medium was replaced by 1 ml of simplified
medium (composition is given in Supplemental Table 2) supplemented
with 50 mM EHNA (to avoid adenosine deamination) and 2 mM
internal standard (theophylline). After 5 minutes to 4 hours, the
extracellular medium was collected and extracted with 2.3 ml of
methanol. Samples were centrifuged at 17,000g for 10 minutes to
remove insoluble materials, and supernatants were filtered and
evaporated to dryness at 37°C under airflow. The dried samples were
dissolved in 100 ml of mobile phase [methanol/KH2PO4 (10 mM pH 4),
20/80 v/v] and filtered beforeHPLC analysis. The detection limit of the
HPLC technique was 17 nM for the adenosine, while the quantifica-
tion limit was 55 nM. This method exhibited linearity (R2 5 0.99) over
the assayed concentration range (100–1000 nM) and demonstrated
good precision, with the relative S.D. being less than 5%.
HPLC Conditions. A Waters 717 plus autosampler was used,
equipped with aWaters 1525 binary HPLC pump, aWaters 2487 dual
l absorbance detector, and a Waters Breeze software. The analysis
was performed using a Halo C18 column (4.6  250 mm, 5 mm;
Interchim, France). The injection volume was 40–50 ml, and the
elution was carried out at 0.8 ml/min isocratically for 10 minutes with
the column temperature maintained at 30°C. Detection wavelengths
were 273 nm for SQAd and 260 nm for adenosine.
Intracellular cAMP Levels. The day before the experiment, two
plateswere seededwithHepG2 cells: a 24-well platewith 200,000 cells
per well, and a 96-well plate with 5000 cells per well.
On the day of the experiment, cells in the 24-well plate were treated
with SQAd NPs, free adenosine, or dextrose as previously described.
After 2 hours, extracellular medium was replaced with simplified
medium containing 50 mM EHNA and broad-range phosphatase
inhibitors (500 mM isobutyl-1-methylxanthine and 100 mM Ro
20-1724). After 1 hour, 10 ml of this extracellular medium was used
to stimulate cells plated in the 96-well plate for 15 minutes. cAMP
intracellular levels were then determined using the cAMP-Glo assay
from Promega. In brief, cells were lysed with 10 ml of cAMP-Glo Lysis
Buffer for 15 minutes with shaking at room temperature. cAMP-Glo
Detection Solution and Kinase-Glo Reagent were then added to all
wells according to the manufacturer’s protocol. Luminescence was
detected using an EnSpire Alpha 2390 plate reader (PerkinElmer).
Results
SQAd NPs. Prepared by nanoprecipitation, SQAd NPs
suspensions were monodisperse, displaying a hydrodynamic
diameter of 71 6 15 nm, a PdI of 0.08 6 0.02, and a drug
loading of 37%.
SQAd Interaction with Human Adenosine Receptors.
The direct interaction of SQAd with human ARs was checked
by radioligand displacement assays. Specific radioligands
were used for each adenosine receptor, and their displacement
was measured in the presence of increasing concentrations of
SQAd bioconjugate or NPs. Results are shown in Fig. 1.
Up to 1 mM, SQAd showed no interaction with any of the
ARs in the assay buffer, whether as a bioconjugate or
assembled as NPs (Fig. 1, A and B, respectively). At and above
10 mM, some displacement became detectable, with both
SQAd bioconjugates and NPs showing a slight preference for
the adenosine A3 receptor (Fig. 1, A and B). Using the Cheng-
Prusoff equation, themagnitude of SQAd (bioconjugate or NP)
affinity for each of these receptors was determined. Results
are given in Table 1. All ligand binding affinities (Ki) were in
the micromolar to millimolar range.
To be as close as possible to the in vitro and in vivo conditions,
SQAd bioconjugates and SQAd NPs were also preincubated for
4 hours at 37°C with FBS prior to the radioligand displacement
assay. It should be noted that the interaction with the
adenosine A2B receptor could not be evaluated under these
conditions due to unspecific interactions between the mem-
branes and the FBS. Regarding the three other receptors, an
interaction with SQAd bioconjugates or NPs could no longer











be detected, even at the highest concentration (Fig. 1, C and
D). Hence, it was concluded that the preincubationwith serum
prevented interaction of SQAd with adenosine receptors.
SQAd NPs Internalization. To follow the cell uptake
of SQAd NPs, radiolabeled NPs were prepared by
co-nanoprecipitation of SQAd and SQ-[3H]-Ad (for more in-
formation, seeMaterials andMethods), with no influence of the
radiolabeled compound on the NP hydrodynamic diameter
(56 6 4 nm) or PdI (0.10 6 0.04). HepG2 cells were then
incubated at 37°C for different times with either radiolabeled
SQAd NPs or [3H]-adenosine. The resulting intracellular
radioactivity is presented in Fig. 2.
Both adenosine and SQAdNPs were internalized by HepG2
cells. However, the cell uptake of SQAdNPs occurred slower
and to a lower extent than free adenosine. Indeed, after
30-minute incubation, the intracellular content in adeno-
sine (and its tritiated metabolites) was 13 times higher than
with SQAd (and its metabolites). After 24 hours, however,
the adenosine-over-SQAd ratio was reduced to a value of
only 3.
For further experiments, fluorescently labeled SQAd NPs
(diameter of 60.86 0.4 nm, PdI of 0.136 0.01) were prepared
by co-nanoprecipitation of SQAd with a fluorescent BODIPY-
cholesteryl ester dye. The fluorescent nanoparticle maximum
excitation and emission wavelengths were 484 and 520 nm,
respectively (Supplemental Fig. 1). NP uptake by HepG2
cells was visualized by confocal microscopy and measured
by flow cytometry under various conditions (Fig. 3). The
fluorescently labeled SQAd NPs were taken up by HepG2
cells (2-hour incubation) (Fig. 3A), whereas no fluorescence
was visible when the cells were incubated with the fluo-
rescent probe alone (Fig. 3B). Hence, the intracellular
fluorescence was considered to correlate well with SQAd
NPs uptake.
Then, considering that adenosine enters the cells via
equilibrative nucleoside transporters (ENTs) (Baldwin et al.,
2004), the cellularmechanism of uptake of SQAdNPswas also
investigated using HepG2 cells treated with dipyridamole, an
ENT inhibitor. After 30 minutes or 2 hours of incubation with
fluorescently labeled NPs, no difference in intracellular
fluorescence was observed between cells preincubated with
orwithout dipyridamole (Fig. 3C), which clearly indicated that
SQAd NPs did not enter the cells via ENTs.
The role of LDLRs was then evaluated by tuning their level
of expression on HepG2 cells. Cells were preincubated for
24 hours with FBS-supplemented medium (containing a
normal level of lipoproteins) and LPDS-supplemented me-
dium (containing low levels of lipoproteins). Cell starvation
using LPDS induced an overexpression of LDLRs, as evident
fromWestern blot (Supplemental Fig. 2). It is noteworthy that
in LPDS-supplemented medium, cells were found to internal-
ize higher levels of fluorescently labeled SQAd NPs (Fig. 3D),
thus demonstrating an influence of LDLR expression level on
SQAd NPs uptake.
SQAd Degradation in Acidic Conditions. Assuming
that, once in the cell, SQAd would undergo hydrolysis in acidic
endo-lysosomal compartments, SQAd degradation was then
evaluated over 24 hours in acidic conditions (pH 4.8) in the
presence or absence of cathepsin B, a typical lysosomal
enzyme able to cleave amide bonds. The percentage of intact
prodrug under these conditions is shown in Fig. 4A.
Fig. 1. Displacement of specific radio-
ligand binding from the human adenosine
receptors A1 (red circle), A2A (orange square),
A2B (yellow triangle), and A3 (green diamond)
by increasing concentrations of SQAd bio-
conjugate (A and C) or SQAd NPs (B and
D) diluted in assay buffer (A and B) or
preincubated for 4 hours at 37°C in FBS (C
and D). Displacement experiments were
performed at 25°C. NSB, nonspecific bind-
ing; TB, total binding. Data represent
mean values 6 S.D. of three independent
experiments.
TABLE 1
SQAd bioconjugate and SQAd NP pKi magnitude for each adenosine
receptor
The pKi values were determined from the radioligand displacement curves using the
Cheng-Prusoff equation.
pKi
A1 A2A A2B A3
SQAd bioconjugate #4 ,5 #4 ,6
SQAd NP ,4 ,4 ,5 ,5











Although almost no bioconversion of the SQAd bioconjugate
could be observed until 6 hours, up to 20% of SQAd was
degraded after 24 hours of incubation in acidic conditions. The
presence of cathepsin B did not influence the degradation
profile over 24 hours. Interestingly, the degradation of SQAd
led to the release of free adenosine (retention time 3.9 min-
utes), which was characterized by HPLC analysis (Fig. 4B).
Hence, SQAd intracellular bioconversion into adenosine should
increase the adenosine intracellular content. And, as a result of
the equilibrium between the intracellular and the extracellular
adenosine levels, it was hypothesized that some adenosine could
be further released in the extracellular compartment.
Adenosine Extracellular Release. Thus, the concentra-
tion of adenosine released in the cell culture medium was then
determined by HPLC in the presence of EHNA, an inhibitor of
adenosine deaminase. After incubation of HepG2 (or hCMEC/
D3) cells with SQAd NPs, free adenosine, or 5% dextrose
solution, the extracellular medium was replaced by 1 ml of a
new simplified medium (composition is given in Supplemental
Table 2) to remove adenosine (eventually resulting from the
release fromSQAdNPs before their capture by the cells). After a
further 5-minute to4-hour incubation, the extracellularmedium
was finally collected to determine the quantity of adenosine
released from the cells after exposure to SQAdNPs or adenosine
(Fig. 5A).
After 5-minute incubation, cells treated with free adenosine
released higher concentrations of adenosine (around 600 nM)
than cells treated with dextrose or SQAd NPs (100–200 nM).
This clearly highlighted the almost instantaneous ability of
the cells to uptake free adenosine, whereas SQAd NP uptake
and cleavage (which results in adenosine metabolite release)
required more time (Fig. 5A). Interestingly, after a longer
incubation time with free adenosine, a decrease in adenosine
release was observed, which likely resulted from a consump-
tion of the overall pool of adenosine by the cells. On the
contrary, after a longer incubation time with SQAd NPs,
higher levels of released adenosine were observed, which
correlated well with an increased intracellular content of
SQAd over time, hence producing a reservoir effect. Of note,
very close results were obtained with hCMEC/D3 cells, a brain
endothelial cell line derived from human temporal lobe micro-
vessels (Supplemental Fig. 3).
To further study the intracellular reservoir effect of aden-
osine produced after incubation with SQAd NPs, cells were
incubated for 2 hours with free adenosine, SQAd NPs, or
dextrose, and the kinetics of adenosine release from the cells
into the extracellular medium was determined. Results are
shown in Fig. 5B. Interestingly, concentrations of released
adenosine after incubation of the cells with dextrose or free
adenosine did not increase over time, thus revealing that
equilibrium was reached during the first minutes post in-
cubation. On the contrary, when the cells were incubated with
SQAd NPs, quantities of adenosine released by the cells
increased over time. This clearly confirmed the reservoir effect
resulting from the intracellular accumulation of SQAd NPs
followed by the progressive cleavage of the SQAd bioconjugate,
allowing a progressive release of free adenosine in the extra-
cellular medium.
Fig. 2. Uptake of radiolabeled SQ-[3H]-adenosine (SQ-[3H]-Ad) NPs (red
circle) or [3H]-adenosine (orange square) by HepG2 cells (37°C over
24 hours). Data represent mean values 6 S.D. of two independent
experiments.
Fig. 3. Cell uptake of fluorescently labeled SQAd NPs by HepG2 cells. (A and B) Confocal microscopy images of HepG2 cells incubated for 2 hours with
fluorescently labeled SQAd NPs (A) or the fluorescent tag BODIPY-cholesteryl ester dye as a control (B), prepared under the same conditions as NPs.
Cell membranes were stained with wheat germ agglutinin Alexa Fluor 555 (red), whereas 49,6-diamidino-2-phenylindole was used to visualize nuclei
(blue). Scale bar, 50 mm. (C and D) Relative fluorescence measured by flow cytometry from HepG2 cells incubated for 30 minutes or 2 hours with
fluorescently labeled SQAd NPs. (C) Cells treated with NPs were incubated in the absence (bright-red bars) or presence (dark-red bars) of dipyridamole
(dipy). (D) Cells were preincubated for 24 hours with FBS-supplemented (bright-red bars) or LPDS-supplemented Dulbecco’s modified Eagle’s medium
(pink bars). Cell autofluorescence was subtracted from each data set. Data represent mean values6 S.D. of three independent experiments. **P, 0.01,
two-way analysis of variance with Tukey’s post hoc test.











A remaining question was whether the released adenosine
in the extracellular medium was capable of interaction with
adenosine receptors on neighboring cells.
Adenosine Receptors Activation. Thus, adenosine re-
ceptor activation was evaluated by measuring the levels of
intracellular cAMP. Indeed, adenosine receptors are GPCRs
known to activate or inhibit adenylate cyclase, hence tuning
intracellular levels of cAMP. As in the previous set of experi-
ments, HepG2 cells were incubated with dextrose, free adeno-
sine, or SQAd NPs for 2 hours and then allowed to release
adenosine during 1 hour in their extracellular medium. This
medium was then used as an adenosine pool to investigate the
interaction, through 15-minute incubation, with other naïve
cells by measuring their intracellular cAMP levels. As can be
seen in Fig. 6, the extracellular medium originating from cells
treated with control vehicle (5 wt. % dextrose) or free adenosine
did not induce major changes in intracellular cAMP levels.
However, extracellularmediumarising from cells treatedwith
SQAd NPs induced a significant increase in cAMP, compar-
atively to vehicle. Interestingly, adenosine levels in extra-
cellular medium originating from cells treated with SQAd
NPs or free adenosine were very close under the conditions
used (2 hours of treatment and 1 hour of release, cf. Fig. 5A).
Hence, adenosine might not be the only factor in the
extracellular medium interacting with GPCRs.
Discussion
This study aimed at clarifying the mechanism of action of
SQAd NPs in vitro. The main objective was to determine
whether SQAd acted directly on ARs as a specific ligand or
indirectly as a prodrug-releasing active adenosine.
By using radioligand displacement experiments, it was found
that SQAd as a bioconjugate or as NPs displayed a rather weak
affinity for human ARs, showing Ki superior to 10
26 M for A3
and 1025 M for all other ARs. As a matter of comparison, the
native ligand adenosine has an affinity of around 1027M for A1,
A2A, and A3 and 10
26 M for A2B (Yan et al., 2003).
More importantly, when SQAd bioconjugate or NPs were
preincubated in serum to mimic the in vivo conditions, no
more binding onto ARs could be detected. This was attributed
to the interaction of SQAd with plasma proteins, especially
with cholesterol-rich lipoproteins, i.e., low-density lipopro-
teins (LDLs) in humans and high-density lipoproteins in
rodents (Sobot et al., 2017b). In silico simulations have
confirmed that the interaction of the squalene-based biocon-
jugates with the LDL was driven by the squalene moiety,
allowing the hydrophilic adenosine to insert deeply into the
LDL hydrophobic core (Yesylevskyy et al., 2018). Thus, LDLs
may hinder the possible interaction of SQAd with ARs. As a
result, the hypothesis that SQAd may act directly on ARs as a
ligand could be rejected.
To assess the second hypothesis related to the progressive
release of adenosine from SQAd NPs after cell capture,
cultured hepatocytes were used. The HepG2 cell line was
chosen because SQAd NPs are concentrated into the liver
tissue after intravenous administration (Gaudin et al., 2015).
It was observed that the cell capture of SQAd NPs was
independent from the ENT adenosine transporters. And as
Fig. 4. (A) Percentage of intact SQAd
after incubation until 24 hours, with or
without cathepsin B (pH 4.8, 37°C). Data
represent mean values 6 S.D. of two
independent experiments. (B) Represen-
tative HPLC chromatogram of partial
activation of SQAd into adenosine (Ad)
(24-hour incubation, pH 4.8, 37°C, in the
presence of cathepsin B). Of note, the
peak corresponding to SQAd is not visible
in the elution conditions used for adeno-
sine detection. AU, Arbitrary Unit.
Fig. 5. Concentrations of adenosine released in the extracellular medium from HepG2 cells exposed to various treatments. (A) Cells were incubated for
indicated times with 100 mM SQAd NPs (red bars), adenosine (Ad) (orange bars), or 5 wt. % dextrose (Dext) (yellow bars), and released adenosine
concentrations were measured 1 hour following cell culture medium renewal. (B) Cells were incubated for 2 hours with 100 mM SQAd NPs (red circles),
adenosine (orange squares), or 5 wt. % dextrose (yellow triangles), and released adenosine concentrations were measured at different times. Data
represent mean values 6 S.D. of three (A) or two (B) independent experiments.











ENTs selectively mediate the bidirectional transport of nucle-
osides, nucleobases, and nucleoside analogs (Boswell-Casteel
and Hays, 2017), the presence of the squalene bulky moiety in
SQAdwas supposed to prevent the interaction of the adenosine
fragment with ENTs. By contrast, the cell internalization of
SQAd NPs was found to occur through the LDLRs.
As LDLRs are known to trigger the cell internalization via
clathrin-dependent endocytosis (Goldstein et al., 1985), it was
quite likely that SQAd followed the same pathway, thus
ending up in endosomes and then lysosomes. This hypothesis
is in perfect agreement with the confocal microscopy images
obtained in this study (Fig. 3A). Once in the lysosomes, SQAd
underwent a slow degradation under acidic conditions.
Even though cathepsin B alone did not accelerate this
proteolytic degradation under tested conditions, its combi-
nation with other enzymes such as cathepsin D (Couvreur
et al., 2006) and proteases may accelerate this phenomenon
in vitro and in vivo. In addition, it was observed that the
intracellular cleavage of SQAd into free adenosine also
resulted in an extracellular release of adenosine, which
gradually increased over time. In other words, SQAd behaves
as an intracellular reservoir, slowly releasing adenosine in
the extracellular medium, probably via ENTs, since these
transporters could act bidirectionally. Interestingly, the
human brain endothelial hCMEC/D3 cell line showed similar
adenosine extracellular release after SQAd NPs internaliza-
tion, which suggests that the interaction of SQAd NPs with
HepG2 cells represents amore general trend also occurring in
other cell types.
Finally, higher cAMP second messenger levels were ob-
served in cells incubated with the extracellular medium
originating from cells treated with SQAd NPs, which clearly
indicated an increased activation of ARs. However, since
adenosine levels in the extracellular medium originating from
cells treated with SQAd NPs or free adenosine were very close
under the conditions used, adenosine might not be the only
factor in the extracellular medium interacting with GPCRs.
In a summary, this study led to a better understanding of
the SQAd NPs mechanism of action, as illustrated in Fig. 7.
Unlike currently proposed agonists and antagonists of
ARs, SQAd NPs do not interact directly with the ARs but
function in a very original way, as a prodrug delivering high
quantities of adenosine into the cells. Hence, cells dispose
of an important intracellular reservoir of adenosine, pro-
gressively releasing the nucleoside which, in turn, can act
as an autocrine or paracrine factor. In conclusion, SQAd
NPs provide an efficient system for prolonged adenosine
delivery, resulting in ARs activation. This new delivery
pathway may open interesting prospects in terms of clinical
applications.
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